COUR Pharmaceutical Development Company, Inc.
5 clinical trials · Sponsor
◉ Watch COUR Pharmaceutical Development Company, Inc.
| Record | Firm | Date |
|---|---|---|
| CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) (NCT06783309) | COUR Pharmaceutical Development Company, Inc. | 2025-05-12 |
| Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis (NCT06106672) | COUR Pharmaceutical Development Company, Inc. | 2024-05-30 |
| CNP-201 in Subjects With Peanut Allergy (NCT05250856) | COUR Pharmaceutical Development Company, Inc. | 2022-03-14 |
| Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis (NCT05104853) | COUR Pharmaceutical Development Company, Inc. | 2022-01-25 |
| Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy (NCT04950504) | COUR Pharmaceutical Development Company, Inc. | 2021-06-02 |
Track COUR Pharmaceutical Development Company, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.